The Technical AnalystExchange: SHZ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Pacific Shuanglin Price, Forecast, Insider, Ratings, Fundamentals & Signals
3.38% CNY30.28
America/New_York / 6 mai 2024 @ 02:46
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 22 055 mill |
| EPS: | 0.930 |
| P/E: | 32.56 |
| Earnings Date: | May 21, 2024 |
| SharesOutstanding: | 728.38 mill |
| Avg Daily Volume: | 5.46 mill |
| RATING 2024-05-06 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Buy | |
| DE: | Neutral | |
| P/E: | Strong Buy | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.91x |
| Company: PE 32.56 | sector: PE 35.84 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.71x |
| Company: PE 32.56 | industry: PE 45.57 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
CNY31.15 (2.89%) CNY0.874 |
| Date: 2024-05-05 |
| Expected Trading Range (DAY) |
|---|
|
CNY 28.93 - 30.87 ( +/- 3.25%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | CNY30.28 (3.38% ) |
| Volume | 8.69 mill |
| Avg. Vol. | 5.46 mill |
| % of Avg. Vol | 159.24 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 000403.SZ
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
000403.SZ
Pacific Shuanglin Bio-pharmacy Co., Ltd. engages in the biochemical engineering, pharmaceutical industry equipment, and medical materials businesses in China. Its lead products include human serum albumin, human immunoglobulin, intravenous human immunoglobulin (PH4), human rabies immunoglobulin, hepatitis B human immunoglobulin, tetanus human immunoglobulin, tianqi analgesic cream, musk herd cream, musk bone paste, anti-inflammatory analgesic cream, dieshangling plasters, and medical gauzes. The company is also involved in the development of porcine pulmonary surfactants, shaqifang compounds, a1-protease inhibitors, human coagulation factor VIII products, and human fibrinogens. In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; real estate development; and electronic product information consultation, as well as in the provision of electricity. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. is based in Taiyuan, China.